US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Agile Therapeutics, Inc.
Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
August 26, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
June 26, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
March 28, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Announces Delisting from Nasdaq
March 25, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
March 21, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
March 20, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
March 13, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
February 22, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
February 15, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
January 23, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
December 12, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
October 26, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
July 26, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
June 26, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
June 23, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
June 15, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
June 13, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
May 25, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
May 22, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
May 11, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
May 08, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
April 28, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
April 26, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
April 10, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
March 22, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AGRX
